DOCSLIB.ORG

13 Drugs Acting on the Skin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
13 Drugs Acting on the Skin 13. Drugs acting on the Skin 13.2 Emollient and barrier preparations 13.2.1 Emollients aqueous cream Aveeno® cream Balneum ® Plus cream Calmurid® cream Cetraben® cream Dermol cream Dermol 500 lotion Doublebase Gel Diprobase® emulsifying ointment E45® bath oil Hydromol® cream Hydromol® ointment Lipobase® cream Liquid paraffin 50% in white soft paraffin Oilatum® QV cream Unguentum M® cream white soft paraffin yellow soft paraffin 13.2.1.1 Emollient bath additives Balneum Plus® bath oil (for use in accordance with the Palliative Care Pain and Symptom Control Guidelines) Dermol Bath Emollient E45® Bath Oil Emulsiderm® bath emollient Hydromol® emollient Oilatum® Oilatum Plus® (Dermatology only ) QV bath oil Drapolene cream® 13.2.2 Barrier preparations Metanium® (Neonatal directorate only ) Sudocrem® 13.3 Topical local anaesthetics and antipruritics calamine cream calamine lotion crotamiton ( Eurax® ) 13.4 Topical corticosteroids - For specialist advice contact dermatology - mild Eurax hydrocortisone cream Fluocinolone acetonide 0.0025% cream Fucidin H cream Fucidin H ointment hydrocortisone 0.5% & 1% hydrocortisone 1% lipocream hydrocortisone 2.5% cream hydrocortisone 2.5% ointment hydrocortisone & clotrimazole ( Canesten HC® ) hydrocortisone & clioquinol ( Vioform-Hydrocortisone® ) hydrocortisone & miconazole ( Daktacort® ) Nystaform HC cream Nystaform HC ointment Timodine cream - moderately potent Alclometasone dipropionate cream Alclometasone dipropionate ointment Betamethasone valerate 0.025% ( Betnovate-RD® ) Calmurid HC cream Clobetasone, oxytetracycline & nystatin ( Trimovate® ) Clobetasone butyrate 0.05% ( Eumovate® ) Fluocinolone acetonide 0.00625% cream Fluocinolone acetonide 0.00625% ointment Fludroxycortide ( Haelan® cream/ointment and tape) - potent Betamethasone valerate 0.1% ( Betnovate-RD® ) Betamethasone valerate scalp application Betnovate C cream Betnovate C ointment Betnovate N cream Betnovate N ointment betamethasone & fusidic acid ( Fucibet® ) Diflucortolone 0.1%cream Diflucortolone 0.1%oily cream Diflucortolone 0.1% ointment Diprosalic scalp application Diprosalic ointment Fluocinolone acetonide 0.025% cream Fluocinolone acetonide 0.025% gel Fluocinolone acetonide 0.025% ointment Fluocinonide FAPG 0.05% cream hydrocortisone butyrate 0.1% ( Locoid® ) Locoid C cream Locoid C ointment Lotriderm cream Mometasone furoate 0.1% ( Elocon® ) (Dermatology only) Synalar C cream Synalar C ointment Synalar N cream Synalar N ointment Triamcinolone & chlortetracycline ( Aureocort® ) Tri-adcortyl cream Tri-adcortyl ointment - very potent Clobetasol shampoo ( Etrivex®) Diflucortolone 0.3% ointment Diflucortolone oily cream 0.3% clobetasol propionate 0.05% ( Dermovate®) clobetasol propionate scalp application 13.5 Preparations for eczema and psoriasis 13.5.1 Preparations for eczema Ichthopaste® bandage (Dermatology only) Alitretinoin (dermatology only – severe hand eczema) 13.5.2 Preparations for psoriasis acitretin (Dermatology only) calcipotriol ( Dermatology only) calcipotriol and betametasone ointment ( Dovobet ®) (Dermatology only) calcitriol (Dermatology only) coal tar solution and salicylic acid in Unguentum M® (Dermatology only) Calamine & coal tar ointment Coal tar 0.5% in yellow soft paraffin Coal tar 1% lotion Coal tar in yellow soft paraffin 0.5, 1, 3, 5, 10, 15, 20 & 25% Coal tar paste Coal tar salicyclic acid ointment Coconut oil BP 90g Dithranol cream 0.1, 0.25, 0.5, 1 and 2% Dithranol in lassars paste ( various strengths generally for in- patient use) Fumaderm tablets 120mg Fumaderm tablets 30mg Lanolin ointment with salicyclic acid Sebco scalp ointment Tacalcitol 4microgram/g ointment Ung SCC Sal ( Dermatology only ) Ung SCC Sal Cap ( Dermatology only ) Zinc & salicylic acid paste BP (lassars paste ) 13.5.3 Drugs affecting the immune response adalimumab (Dermatology only) - Follow restricted high cost drug procedure when prescribing adalimumab infliximab ( Dermatology only) Follow restricted high cost drug procedure when prescribing infliximab ciclosporin etanercept (Dermatology only) - Follow restricted high cost drug procedure when prescribing etanercept methoxsalen or methoxypsoralen (Dermatology only) methotrexate mycophenolate ( Consultant Dermatologist only) pimecrolimus 1% cream (Consultant Dermatologists only ) tacrolimus 0.03% and 0.1% ointment (Consultant Dermatologists only ) -if GP is asked to start treatment please issue Tacrolimus ointment Prescribing Guidelines tacalcitol (Dermatology only) 13.6 Acne and rosacea 13.6.1 Topical preparations for acne adapalene benzoyl peroxide 2.5-10% Clinidamycin 1% lotion Clinidamycin 1% topical solution Isotretinoin 0.05% gel Quinoderm® cream tretinoin ( Retin-A® ) (Dermatology only ) Zineryt topical solution 13.6.2 Oral preparations for acne Co-cyprindiol tablets 2000/35 Erythromycin 2% topical solution isotretinoin (Dermatology only ) lymecycline ( Dermatology only ) minocycline ( Aknemin ®) (Dermatology only ) 13.7 Preparations for warts and calluses Condyline® (GUM clinic only ) Duofilm® imiquimod (Aldara®) (GUM clinic only ) Silver Nitrate 75% caustic applicator Silver Nitrate 95% caustic applicator Warticon® including Warticon Fem® (GUM clinic only ) 13.8 Sunscreens and camouflagers 13.8.1 Sunscreen preparations Beta-carotene 25mg capsules Dundee Reflective sunscreen [unlicensed preparation] (Dermatology only) E45 Sun® Reflective sunscreen RoC Sante Soleil® Sunscreen SPF 50+ (Sunsense Ultra) Uvistat® cream and Uvistat® Ultrablock cream Miscellaneous beta-carotene ( Dermatology only ) methyl-5-aminolevulinate (Metvix® cream) (Dermatology only) 13.9 Shampoos and some other scalp preparations Alphosyl 2 in 1 shampoo Capasal shampoo Ceanel Concentrate® Coal tar extract 2% shampoo (T-gel®) Compound coconut oil scalp ointment (Dermatology only ) Polytar® AF shampoo Selenium 2.5% shampoo Hirsuitism Nizoral® Polytar® liquid Ung SCC Sal Cap (for scalp) (Dermatology only ) eflornithine ( Vaniqa® ) cream (second line use for Endocrine, Skin Endocrine clinics and Dr Polson only ) -if GP is asked to start treatment please issue Eflornithine cream Prescribing Guidelines 13.10 Anti-infective skin preparations 13.10.1 Antibacterial preparations mupirocin 2% cream 13.10.1.1 Antibacterial preparations only used topically mupirocin 2% ointment polyfax ointment silver sulfadiazine 1% 13.10.1.2 Antibacterial preparations also used chlortetracycline 3% ( Dermatology only ) systemically fusidic acid 2% (Dermatology only ) metronidazole 0.75% gel ( Zyomet®) metronidazole 0.8% gel metronidazole 1% cream 13.10.2 Antifungal preparations amorolfine nail lacquer (Dermatology only ) clotrimazole econozole nitrate ketoconazole 2% cream miconazole nitrate nystatin nystaform cream salicylic acid ointment terbinafine 1% cream 13.10.3 Antiviral preparations aciclovir 13.10.4 Parasiticidal preparations malathion ( Derbac M®) (second line treatment for scabies; first line treatment for head lice) phenothrin 0.2% solution 13.10.5 Preps for minor cuts/abrasions permethrin ( Lyclear® ) (first line treatment for scabies; second line treatment for head lice) cetrimide povidone iodine proflavine cream BPC 13.11 Disinfectants and cleansers – Contact Infection Control for advice 13.11.1 Alcohols and saline industrial methylated spirit BP sodium chloride surgical spirit BP 13.11.2 Chlorhexidine salts ChloraPrep® (A&E department only ) chlorhexidine 13.11.3 Cationic surfactants and soaps cetrimide 13.11.4 Chlorine and iodine povidone-iodine sodium hypochlorite 13.11.5 Phenolics triclosan 13.11.6 Astringents, oxidisers and dyes hydrogen peroxide potassium permanganate 13.11.7 Preparations for promotion of wound healing (see BNF) 13.11.8 Miscellaneous glutaraldehyde 13.12 Antiperspirants aluminium salts glycopyrronium bromide triethanolamine solution ( Dermatology only) 13.13 Wound Management - contact Tissue Viability Nurse or Pharmacy for advice 13.15 Miscellaneous Sulfamethoxypridazine (unlicensed – Dermatology only ) Sulfapyridine ( unlicensed – Dermatology only ) .
Load more

Recommended publications
  • Chlorhexidine Soap Instructions
    Pre-Operative Bathing Instructions Infection Prevention Because skin is not sterile, we need to be sure that your skin is as free of germs as possible before your admission. You can reduce the number of germs on your skin and decrease the risk of surgical site infection by preparing your skin with a special soap called chlorhexidine gluconate (CHG). The instructions for use are attached. What is CHG? CHG is a chemical antiseptic that is effective on both gram-positive and gram-negative bacteria. It is both bacteriocidal (kills) and bacteriostatic (stops reproductions) of any bacteria on the skin. CHG is in several products such as mouthwash, contact lens solution, wound wash, acne skin wash topical skin cleansers (chloraprep-what is used to clean your skin before an IV), thus we do not expect using this soap will cause skin irritation but please speak with your primary care physician to discuss any allergies. Studies show that repeated use of CHG soap enhances the ability of CHG to reduce bacterial counts on the skin; not only during the immediate period after the shower, but for a number of hours afterward. Studies suggest that patients may benefit from bathing or showering with CHG soap for at least 3 days before surgery in order to achieve the most benefit. It is unknown whether using CHG soap for less than or more than 3 days is beneficial. We recommend 3 days of treatment but understand this is not always possible and bathing the night before and the day of using CHG is acceptable. CHG soap can be purchased at any local pharmacy.
    [Show full text]
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • A Left/Right Comparison of Twice-Daily Calcipotriol Ointment and Calcitriol Ointment in Patients with Psoriasis: the Effect on Keratinocyte Subpopulations
    Acta Derm Venereol 2004; 84: 195–200 INVESTIGATIVE REPORT A Left/Right Comparison of Twice-Daily Calcipotriol Ointment and Calcitriol Ointment in Patients with Psoriasis: The Effect on Keratinocyte Subpopulations Mannon E.J. FRANSSEN, Gys J. DE JONGH, Piet E.J. VAN ERP and Peter C.M. VAN DE KERKHOF Department of Dermatology, University Medical Centre Nijmegen, The Netherlands Vitamin D3 analogues are a first-line treatment of Calcipotriol (Daivonex1,50mg/g ointment, Leo chronic plaque psoriasis, but so far, comparative clinical Pharmaceutical Products, Denmark) has been investi- studies on calcipotriol and calcitriol ointment are sparse, gated intensively during the last decade, and has proven and in particular no comparative studies are available on to be a valuable tool in the management of chronic cell biological effects of these compounds in vivo. Using plaque psoriasis. A review by Ashcroft et al. (1), based on flow cytometric assessment, we investigated whether these a large number of randomized controlled trials, showed compounds had different effects on the composition and that calcipotriol was at least as effective as potent DNA synthesis of epidermal cell populations responsible topical corticosteroids, 1a,-25-dihydroxycholecalciferol for the psoriatic phenotype. For 8 weeks, 20 patients with (calcitriol), short-contact dithranol, tacalcitol and coal psoriasis vulgaris were treated twice daily with calcipo- tar. Recently, Scott et al. (2) presented an overview of triol and calcitriol ointment in a left/right comparative studies on the use of calcipotriol ointment in the study. Before and after treatment, clinical assessment of management of psoriasis. They reconfirmed the super- target lesions was performed, together with flow cyto- ior efficacy of a twice-daily calcipotriol ointment metric analysis of epidermal subpopulations with respect regimen to the treatments as mentioned above, and to keratin (K) 10, K6, vimentin and DNA distribution.
    [Show full text]
  • Health Evidence Review Commission's Value-Based Benefits Subcommittee
    Health Evidence Review Commission's Value-based Benefits Subcommittee September 28, 2017 8:00 AM - 1:00 PM Clackamas Community College Wilsonville Training Center, Room 111-112 29373 SW Town Center Loop E, Wilsonville, Oregon, 97070 Section 1.0 Call to Order AGENDA VALUE-BASED BENEFITS SUBCOMMITTEE September 28, 2017 8:00am - 1:00pm Wilsonville Training Center, Rooms 111-112 29353 SW Town Center Loop E Wilsonville, Oregon 97070 A working lunch will be served at approximately 12:00 PM All times are approximate I. Call to Order, Roll Call, Approval of Minutes – Kevin Olson 8:00 AM II. Staff report – Ariel Smits, Cat Livingston, Darren Coffman 8:05 AM A. Chronic Pain Task Force meeting report B. Errata C. Retreat III. Straightforward/Consent agenda – Ariel Smits 8:15 AM A. Consent table B. Straightforward Modifications to the Prioritized List Changes: Continuous Glucose Monitoring in Diabetes Mellitus C. Straightforward changes to the PPI guideline for Barrett’s esophagus with dysplasia D. Tobacco cessation guideline clarification IV. Advisory Panel reports 8:25 AM A. OHAP 1. 2018 CDT code placement recommendations V. Previous discussion items 8:30 AM A. Consideration for prioritization on lines 500/660, Services with Minimal or No Clinical Benefit and/or Low Cost-Effectiveness 1. New medications for the treatment of Duchenne muscular dystrophy i. deflazacort (Emflaza) ii. etepliren (Exondys 51) VI. New discussion items 9:30 AM A. Testicular prostheses B. Capsulorrhaphy for recurrent shoulder dislocation C. Transcutaneous neurostimulators D. Physical therapy for interstitial cystitis E. Acute peripheral nerve injuries F. SOI on role of Prioritized List in Coverage G.
    [Show full text]
  • Identification of Candidate Agents Active Against N. Ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N
    RESEARCH ARTICLE Identification of Candidate Agents Active against N. ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N. ceranae Infected Cultured Cells Sebastian Gisder, Elke Genersch* Institute for Bee Research, Department of Molecular Microbiology and Bee Diseases, Hohen Neuendorf, Germany * [email protected] Abstract OPEN ACCESS Many flowering plants in both natural ecosytems and agriculture are dependent on insect Citation: Gisder S, Genersch E (2015) Identification of Candidate Agents Active against N. ceranae pollination for fruit set and seed production. Managed honey bees (Apis mellifera) and wild Infection in Honey Bees: Establishment of a Medium bees are key pollinators providing this indispensable eco- and agrosystem service. Like all Throughput Screening Assay Based on N. ceranae other organisms, bees are attacked by numerous pathogens and parasites. Nosema apis is Infected Cultured Cells. PLoS ONE 10(2): e0117200. a honey bee pathogenic microsporidium which is widely distributed in honey bee popula- doi:10.1371/journal.pone.0117200 tions without causing much harm. Its congener Nosema ceranae was originally described Academic Editor: Wolfgang Blenau, Goethe as pathogen of the Eastern honey bee (Apis cerana) but jumped host from A. cerana to A. University Frankfurt, GERMANY mellifera about 20 years ago and spilled over from A. mellifera to Bombus spp. quite recent- Received: October 8, 2014 ly. N. ceranae is now considered a deadly emerging parasite of both Western honey bees Accepted: December 20, 2014 and bumblebees. Hence, novel and sustainable treatment strategies against N. ceranae are Published: February 6, 2015 urgently needed to protect honey and wild bees.
    [Show full text]
  • 4. Antibacterial/Steroid Combination Therapy in Infected Eczema
    Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • Clioquinol: Summary Report
    Clioquinol: Summary Report Item Type Report Authors Gianturco, Stephanie L.; Pavlech, Laura L.; Storm, Kathena D.; Yoon, SeJeong; Yuen, Melissa V.; Mattingly, Ashlee N. Publication Date 2020-01 Keywords Clioquinol; Compounding; Food, Drug, and Cosmetic Act, Section 503B; Food and Drug Administration; Outsourcing facility; Drug compounding; Legislation, Drug; United States Food and Drug Administration Rights Attribution-NoDerivatives 4.0 International Download date 24/09/2021 22:12:31 Item License http://creativecommons.org/licenses/by-nd/4.0/ Link to Item http://hdl.handle.net/10713/12091 Summary Report Clioquinol Prepared for: Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 2U01FD005946 Prepared by: University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) University of Maryland School of Pharmacy January 2020 This report was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005946) totaling $2,342,364, with 100 percent funded by the FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the FDA/HHS or the U.S. Government. 1 Table of Contents REVIEW OF NOMINATIONS ................................................................................................... 4 METHODOLOGY ...................................................................................................................
    [Show full text]
  • Hereditary Gingival Fibromatosis CASE REPORT
    Richa et al.: Management of Hereditary Gingival Fibromatosis CASE REPORT Hereditary Gingival Fibromatosis and its management: A Rare Case of Homozygous Twins Richa1, Neeraj Kumar2, Krishan Gauba3, Debojyoti Chatterjee4 1-Tutor, Unit of Pedodontics and preventive dentistry, ESIC Dental College and Hospital, Rohini, Delhi. 2-Senior Resident, Unit of Pedodontics and preventive dentistry, Oral Health Sciences Centre, Post Correspondence to: Graduate Institute of Medical Education and Research , Chandigarh, India. 3-Professor and Head, Dr. Richa, Tutor, Unit of Pedodontics and Department of Oral Health Sciences Centre, Post Graduate Institute of Medical Education and preventive dentistry, ESIC Dental College and Research, Chandigarh, India. 4-Senior Resident, Department of Histopathology, Oral Health Sciences Hospital, Rohini, Delhi Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Contact Us: www.ijohmr.com ABSTRACT Hereditary gingival fibromatosis (HGF) is a rare condition which manifests itself by gingival overgrowth covering teeth to variable degree i.e. either isolated or as part of a syndrome. This paper presented two cases of generalized and severe HGF in siblings without any systemic illness. HGF was confirmed based on family history, clinical and histological examination. Management of both the cases was done conservatively. Quadrant wise gingivectomy using ledge and wedge method was adopted and followed for 12 months. The surgical procedure yielded functionally and esthetically satisfying results with no recurrence. KEYWORDS: Gingival enlargement, Hereditary, homozygous, Gingivectomy AA swollen gums. The patient gave a history of swelling of upper gums that started 2 years back which gradually aaaasasasss INTRODUCTION increased in size. The child’s mother denied prenatal Hereditary Gingival Enlargement, being a rare entity, is exposure to tobacco, alcohol, and drug.
    [Show full text]
  • Profile of Clinical Efficacy and Safety of Topical Tacalcitol
    leone 9-06-2005 14:07 Pagina 13 ACTA BIO MED 2005; 76; 13-19 © Mattioli 1885 U PDATE Profile of clinical efficacy and safety of topical tacalcitol Giovanni Leone, Alessia Pacifico Phototherapy Service, San Gallicano Dermatological Institute, IRCCS, Rome, Italy Abstract. Several topical treatments such as ointments, keratolytics, dithranol, tar, corticosteroids and Vita- min D3 analogues are commonly used in the treatment of mild and/or moderate psoriasis. These treatments can be associated with a variety of local and systemic side effects, as well as to very often unsatisfactory re- sults. The purpose of this critical review of the literature is to evaluate the efficacy and tolerability of the syn- thesis of new analogues of the Vitamin D3 Tacalcitol, which is formulated in ointment form at a concentra- tion of 4 μg/g, for the treatment of mild and/or moderate psoriasis (involvement of <20% of the surface of the skin) and to evaluate whether this drug can be used in the treatment of other skin conditions. Based on existing data in the literature, Tacalcitol is an effective drug for the topical treatment of psoriasis and is also able to ensure that the effects last over time, even after treatment has stopped. Tacalcitol is also well tolerat- ed because the onset of side effects, such as local irritation, pruriginous or burning sensations, were reported in only a small percentage of the subjects who were treated. Lastly, the marked regulatory effects it has on the proliferation and differentiation of keratinocytes, as well as on the immunocompetent cells, has led to suggestions that Tacalcitol may be used in other keratinisation disorders and in some hyperproliferative skin diseases.
    [Show full text]